May 14, 2019 — InvestorsHub NewsWire — Microcap Speculators — According to a recent article in The New York Post, major retailers are “angling for a piece of the exploding CBD industry, which is expected to more than double to $2.1 billion by next year as consumers pay premium prices for products to treat maladies ranging from arthritis to ADHD. Till now, the lion’s share of the CBD market has been going to smaller mom-and-pop shops. But a few bigger chains, including Walgreens, CVS and GNC, have begun selling CBD-infused topical creams that treat wrinkles and pain in states where they’re allowed, including New York.
Looking at opportunities in the CBD market for investors to start researching, Real Brands (USOTC: RLBD) jumps out. The company gives you all the benefit of the growing market without some of the risk producers face. RLBD is a branding company that is growing its portfolio of CBD brands by the day. The company has strong management with a solid background in branding and the beverage industry and plans to expand their holdings focusing on at least three CBD Categories: smokables, edibles and topical balms and lotions. The company recently updated their logo and brand identity. It is also developing an E-Commerce website and plans to launch it during the early part of the second quarter (which if you’re paying attention could be any day now) on their newly acquired domain name, to support online sales of a variety of smokable, edible, and topical CBD derived from Hemp based products for each of their brands. Start your research today.
Today we are highlighting: Real Brands, Inc. (USOTC: RLBD), Aphria (NYSE: APHA), HEXO Corp. (AMEX: HEXO), Auxly Cannabis Group Inc. (CBWTF), and Cara Therapeutics (NASDAQ: CARA).
Real Brands, Inc. (USOTC: RLBD) (Market Cap: $12.488M; Share Price: $0.0849) is first and foremost a marketing and branding company, which has been slowly building its portfolio of trademarked brand names that could each represent on their own major partnerships and joint ventures going forward.
Jerry Pearring, the CEO of Real Brands commented, “As the demand for CBD infused products continues to grow, we intend to create marketing strategies in at least three CBD Categories: smokables, edibles and topical balms and lotions.”
Products like CBD gums are something which golfers Tiger Woods and Phil Mickelson are rumored to be chewing. The non-psychoactive health benefits of CBD are appealing for golfers.
That’s why RLBD announcing that PGA professional Scott Piercy is coming aboard as Brand Ambassador is big news. In March ‘19, he made a further commitment by making a long-term investment into Real Brands.
RLBD is launching a CBD beverage. The audit on the horizon means this could also be another major event for investors to pay attention to. Start your research today.
OTHER CANNABIS COS TO RESEARCH INCLUDE:
Aphria Inc. (NYSE: APHA) (Market Cap: $1.753B; Share Price: $7.01) shares fell after the Canadian cannabis company reported fiscal third-quarter results. It posted a C$108.2 million ($81.1 million) loss for its fiscal third quarter, or 43 cents a share, after a profit of C$12.9 million, or 8 cents a share, in the same period a year ago. Revenue climbed to C$73.6 million from C$10.3 million in the first full quarter of Canadian legal cannabis. But the company sold less cannabis than a year ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average retail selling price for medical cannabis increased to C$8.03 per gram from C$7.51, primarily because of higher oil sales.
In April, it announced that the previously announced take-over bid (the “Offer”) by Green Growth Brands Inc. (“GGB”) has failed to meet the statutory minimum tender condition and has now expired and is terminated. As previously announced on April 15, 2019, the company entered into a definitive agreement with GGB to accelerate the expiry date of the Offer to April 25, 2019, as well as to terminate certain arrangements with GA Opportunities Corp. (“GAOC”) for consideration of $89.0 million payable on future dates as set out in the April 15th press release. The Offer is now expired and terminated and no longer open to any Aphria shareholder to tender their shares. Accordingly, GGB will not be taking up any securities that may have been tendered to the Offer. GGB will promptly return to the securityholder any Aphria shares tendered and not withdrawn during the period from the commencement of the Offer up to the expiry time of the Offer.
HEXO Corp (AMEX: HEXO) (Market Cap: $1.458B; Share Price: $6.87) and Newstrike Brands Ltd. (“Newstrike”) (TSX-V: HIP) had announced in March that they had entered into a definitive arrangement agreement (the “Arrangement Agreement”) under which HEXO will acquire all of Newstrike’s issued and outstanding common shares in an all-share transaction valued at approximately $263 million. The Transaction gives HEXO the capacity to produce approximately 150,000 kg of high-quality cannabis annually. The Transaction also provides HEXO access to four cutting-edge production campuses totalling close to 1.8 million sq. ft. of near-term cultivation space and diversified growing and production techniques. This is in addition to HEXO’s 579,000 sq. ft. facility for a manufacturing and product development centre of excellence in Belleville, Ontario. HEXO Corp has its headquarters in Gatineau Canada, and it produces and sells most of its cannabis products in the country.
The Brantford, Ontario-based Newstrike Brands were granted a cultivation license on 16 December 2016, and the company expects its harvest to be about 42,000 kg of cannabis. Although the company has not been around for long compared to HEXO, it has high capacity for cannabis production. HEXO recently announced that it had completed the first harvest in its 1 million sq. ft. expansion, marking an important execution milestone in the company’s continuous growth.
HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. As one of the largest licensed cannabis companies in Canada, HEXO Corp operates with 1.8 million sq. ft of facilities in Ontario and Quebec and a foothold in Greece to establish a Eurozone processing, production and distribution center.
Auxly Cannabis Group Inc. (CBWTF) (Market Cap: $371.291M; Share Price: $0.60425) released its fourth quarter and full year 2018 financial results in March 2019. These filings and additional information regarding Auxly are available for review on SEDAR. For the year ended December 31, 2018, Auxly recognized $747,000 of research revenues from the recently completed acquisition of KGK in the third quarter of 2018. Auxly realized a gross loss of $188,000 in 2018 comprised of revenues less KGK expenses of $1,078,000 in support of third-party research contracts.
On April 8, it announced that its wholly-owned subsidiary, Robinsons Cannabis Inc. (“Robinsons”), has been granted standard cultivation and processing licenses by Health Canada pursuant to the Cannabis Act and Cannabis Regulations. The licenses give Robinsons the ability to begin cultivation at its fully constructed 27,700 square-foot facility in Kentville, Nova Scotia, which was purpose-built to produce high-quality cannabis.
Auxly Cannabis Group Inc. operates as a cannabis streaming company. It provides funding for cannabis production; and holds contractual rights and minority equity interest relating to the operation of cannabis facilities. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Cara Therapeutics, Inc. (NASDAQ: CARA) (Market Cap: $734.212M; Share Price: $18.47), a clinical-stage biopharmaceutical company, has a comprehensive report issued by Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies. Cara Therapeutics focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors.
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with RLBD dated 8/31/18. The agreement calls for $100,000 note issued to Regal Consulting, and 2,500,000 restricted 144 shares of RLBD for three months of service. Regal has elected to convert $73,000 of principal of the $100,000 note into 2,761,872 Restricted 144 shares of RLBD. Regal Consulting has agreed to a twelve- month term consulting agreement with RLBD dated 1/4/2019. The agreement calls for $10,000 in cash and 500,000 shares per month. All payments were made directly by Real Brands, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. RLBD was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: [email protected]
Country: United States
SOURCE: Microcap Speculators